Indian consumer goods company selling Ayurvedic/natural health, personal-care and food products (Chyawanprash, Real juices).
Indian consumer goods company selling Ayurvedic/natural health, personal-care and food products (Chyawanprash, Real juices).
Sells through a network of distributors who stock small neighbourhood shops across India, giving reach into villages that large multinationals find costly. Health supplements sit alongside a broad personal-care range. The Burman family, which founded the company in 1884, remains the controlling shareholder.
In one line: India's smaller Nature's Bounty/Church & Dwight hybrid.
Moat: narrow (brand, distribution). A trusted heritage Ayurvedic brand with deep rural distribution built over more than a century.
Headquarters: Ghaziabad, India · Founded: 1884 · Employees: 14,675
Size Dabur India (DABUR.NS) is an India Consumer Staples company (Household/Personal Care) with a market value of $7.16B, the 166th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹379.25 on 18 Nov 2026.
Performance Over six months the shares fell 16.2%, against +15.1% for the median peer and +3.8% for the India market (cap-weighted) — 3rd lowest of 21 in its peer set.
Growth Revenue grew 8.9% over the last twelve months (peer median +6.2%); the operating margin is 15.0% (peer median 13.8%).
Valuation It trades at 31.8× forward earnings against a peer median of 24.3× (7th most expensive of 20).
Price implies For today's price to make sense, revenue must grow about 27% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is +21 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 4.7 points above its cost of capital (13.2% WACC).
Next results Next results expected around 4 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹139B | ₹131B | ₹124B | ₹123B | ₹115B |
| Revenue growth | — | +5% | +1% | +7% | — |
| Gross profit | ₹48.0B | ₹39.8B | ₹37.7B | ₹38.3B | ₹33.8B |
| EBITDA | ₹25.7B | ₹24.1B | ₹22.6B | ₹23.6B | ₹21.6B |
| Net income | ₹20.2B | ₹19.0B | ₹17.7B | ₹18.4B | ₹17.1B |
| Free cash flow | n/a | ₹23.2B | ₹16.5B | ₹17.3B | ₹13.0B |
| Capital expenditure | n/a | ₹4.20B | ₹5.70B | ₹5.64B | ₹5.09B |
| Total debt | ₹14.4B | ₹12.9B | ₹9.50B | ₹13.7B | ₹11.7B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Dabur India DABUR.NS | $7.16B | -16% | +9% | 15% | 31.8× | 27.4% |
| Marico MARICO.NS | $12.6B | +9% | +20% | 16% | 52.2× | 28.3% |
| Godrej Consumer Products GODREJCP.NS | $9.75B | -12% | +12% | 18% | 39.1× | 32.9% |
| Hindustan Unilever HINDUNILVR.NS | $50.0B | -11% | +6% | 21% | 41.4× | 27.4% |
| Emami EMAMILTD.NS | $1.94B | -5% | +13% | 20% | 23.4× | 21.5% |
| Colgate-Palmolive (India) COLPAL.NS | $4.91B | -23% | +9% | 28% | 32.4× | 31.1% |
| Patanjali Foods PATANJALI.NS | $4.64B | -15% | +18% | 4% | 30.0× | n/a |
| Bajaj Consumer Care BAJAJCON.NS | $560M | -24% | +29% | 22% | 19.7× | 14.8% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | DABUR.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +0.2% | +8.6% | 8th lowest of 21 |
| 6-month return | -16.2% | +15.1% | 3rd lowest of 21 |
| Distance from 52-week high | -29.0% | -7.9% | 5th lowest of 21 |
| Revenue growth (TTM) | +8.9% | +6.2% | 8th highest of 21 |
| Operating margin | 15.0% | 13.8% | 9th highest of 21 |
| Forward P/E | 31.8× | 24.3× | 7th most expensive of 20 |
| Growth the price implies (Req g, 7 yrs) | 27.4% | 4.1% | 4th most demanding of 20 |
| Growth delivered (Del g) | +6.6% | +5.4% | 10th highest of 20 |
| Hurdle (Req g minus delivered) | +20.8 pp | -2.6 pp | 3rd most demanding of 20 |
| ROIC minus cost of capital | +4.7 pp | +4.2 pp | 10th highest of 20 |
| EV / EBITDA | 24.8× | 13.9× | 3rd most expensive of 19 |
| Net debt / EBITDA | -1.4× | -0.1× | 4th least indebted of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Dabur India DABUR.NS | India | $7.16B | -16% | +9% | 15% | 31.8× | 27.4% | +6.6% |
| e.l.f. Beauty ELF | United States | $6.73B | +124% | +40% | 14% | 34.3× | 24.1% | +38.8% |
| APR 278470.KS | South Korea | $6.66B | -45% | +119% | 24% | 16.2× | -2.3% | +47.3% |
| Amorepacific 090430.KS | South Korea | $6.01B | 0% | +10% | 9% | 24.4× | 3.6% | -0.8% |
| Reynolds Consumer Products REYN | United States | $5.28B | +15% | +2% | 14% | 15.3× | 0.8% | +2.7% |
| Godrej Consumer Products GODREJCP.NS | India | $9.75B | -12% | +12% | 18% | 39.1× | 32.9% | +6.6% |
| Cupid CUPID.NS | India | $5.22B | +218% | +125% | 33% | n/a | n/a | n/a |
| Colgate-Palmolive (India) COLPAL.NS | India | $4.91B | -23% | +9% | 28% | 32.4× | 31.1% | +4.5% |
| Shiseido 4911.T | Japan | $10.8B | +47% | +6% | 6% | 35.1× | 12.7% | +1.0% |
| Mao Geping Cosmetics 1318.HK | Hong Kong | $4.67B | -8% | +32% | 31% | 14.3× | 4.1% | +41.1% |
| Interparfums IPAR | United States | $4.28B | +48% | +3% | 18% | 28.4× | 10.5% | +22.5% |
| Puig Brands PUIG.MC | Spain | $12.4B | +31% | +4% | 16% | 18.1× | -2.6% | +11.7% |
| Marico MARICO.NS | India | $12.6B | +9% | +20% | 16% | 52.2× | 28.3% | +11.1% |
| Unicharm 8113.T | Japan | $13.0B | +20% | +2% | 11% | 26.9× | 0.1% | +5.4% |
| Clorox CLX | United States | $13.1B | +15% | +6% | 14% | 18.9× | 4.1% | -1.8% |
| Rohto Pharmaceutical 4527.T | Japan | $3.87B | +8% | +7% | 12% | 16.5× | -2.8% | +13.7% |
| Lion 4912.T | Japan | $3.85B | +44% | +6% | 8% | 24.3× | 0.9% | +3.5% |
| Coty COTY | United States | $3.71B | +116% | 0% | 5% | 13.5× | 9.8% | +4.6% |
| Hengan Int'l 1044.HK | Hong Kong | $3.27B | -12% | +2% | 11% | 9.1× | -8.2% | -0.1% |
| Kobayashi Pharmaceutical 4967.T | Japan | $3.25B | +20% | +2% | 6% | 48.7× | 18.0% | +1.9% |
| Proya Cosmetics 603605.SS | China | $2.87B | -13% | +2% | 13% | 10.9× | -5.3% | +23.1% |